Population-Based Epidemiologic Analysis of Acute Pyelonephritis

Christopher A. Czaja, Delia Scholes, Thomas M. Hooton, and Walter E. Stamm

1Division of Allergy and Infectious Diseases, University of Washington, and 2Center for Health Studies, Group Health Cooperative, Seattle, Washington; and 3Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida

(See the editorial commentary by Foxman et al. on pages 281–3)

**Background.** Acute pyelonephritis is a potentially severe disease for which there are few population-based studies. We performed a population-based analysis of trends in the incidence, microbial etiology, antimicrobial resistance, and antimicrobial therapy of outpatient and inpatient pyelonephritis.

**Methods.** A total of 4887 enrollees of Group Health Cooperative, based in Seattle, Washington, who received an *International Classification of Diseases, Ninth Revision, Clinical Modification*, diagnosis of acute pyelonephritis from 1997 through 2001 were identified using computerized records. Diagnoses were linked to urine culture and antibiotic prescription data. Case patients (n = 3236) included subjects who had received an inpatient or culture-confirmed outpatient diagnosis of acute pyelonephritis.

**Results.** Among the female population, annual rates of outpatient and inpatient pyelonephritis were 12–13 cases per 10,000 population and 3–4 cases per 10,000 population, respectively; among the male population, the rates were 2–3 cases per 10,000 population and 1–2 cases per 10,000 population, respectively. Rates were relatively stable from year to year. Incidence was highest among young women, followed by infants and the elderly population. The ratio of outpatient to inpatient cases was highest among young women (ranging from 5:1 to 6:1). *Escherichia coli* caused 80% of cases of acute pyelonephritis in women and 70% of cases in men and was less dominant in older age groups. Among *E. coli* strains, the rate of ciprofloxacin resistance increased from 0.2% of isolates to 1.5% of isolates (P = .03), and the rate of trimethoprim-sulfamethoxazole resistance decreased from 25% of isolates to 13% of isolates (P < .01) from 1997 to 2001. Among outpatient cases, the rate of fluoroquinolone use increased from 35% to 61%, whereas the rate of trimethoprim-sulfamethoxazole use decreased from 53% to 32% over the 5-year period (P < .01).

**Conclusions.** This comprehensive, population-based analysis adds to our limited knowledge of the epidemiology of acute pyelonephritis, especially among outpatients, in whom the majority of cases now occur.

Acute pyelonephritis is a severe form of urinary tract infection (UTI) with symptoms that range from mild discomfort to life-threatening illness or death [1]. Complications may result in chronic renal scarring and impairment of renal function [2–6], especially in children. The annual societal cost of treatment of acute pyelonephritis was recently estimated to be $2.14 billion in the United States [7]. Despite the morbidity related to this disease, epidemiological data on incidence and causal organisms are limited. Earlier studies have focused primarily on disease associated with hospitalization [8–12]. To our knowledge, only 2 population-based studies have included outpatients [13, 14]. However, outpatient treatment is increasingly advocated and practiced in most populations [15–22].

There are also relatively few data available on the antimicrobial-resistance patterns of bacterial strains causing acute pyelonephritis. Because resistance to trimethoprim-sulfamethoxazole among *Escherichia coli* strains causing acute cystitis and pyelonephritis is increasing and is associated with treatment failure [23–27], guidelines recommend the use of alternative agents for treatment of UTI when drug resistance may be likely [15]. Consequently, fluoroquinolones are becoming the predominant therapy for UTI in many areas, and an increased incidence of fluoroquinolone resistance may soon follow [28–30].
We undertook this study to better describe the epidemiology of acute pyelonephritis in a well-defined US population over a 5-year period, including the incidence and microbial etiology among both outpatients and inpatients. Trends in antimicrobial resistance and antimicrobial use for therapy of pyelonephritis were also evaluated.

**METHODS**

**Study setting.** Group Health Cooperative (GH; Seattle, WA) is a health maintenance organization serving >525,000 enrollees in Washington and Idaho. The age, sex, and racial distribution (82% white and 5% Hispanic) of the enrollees are similar to those of the communities that GH serves. Eighty-two percent of GH enrollees are college-educated, which is a slightly larger percentage than that for the surrounding population of King County, Washington (where 63% of the population is college-educated).

**Study subjects and case definitions.** Subjects included all GH enrollees with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis of acute pyelonephritis recorded in the GH computerized database during the period 1997–2001. Codes 590.1 (acute pyelonephritis, without lesion of renal medullary necrosis), 590.11 (acute pyelonephritis, with lesion of renal medullary necrosis), and 590.8 (pyelonephritis, unspecified) were included. We did not distinguish between primary and secondary diagnoses. The age, sex, date of diagnosis, and treatment setting of each subject were gathered from the computerized record.

The case definition of acute pyelonephritis differed for outpatient and inpatient cases. Outpatients were subjects who received an ICD-9-CM diagnosis of acute pyelonephritis in the outpatient setting, including the emergency department, in combination with urine culture confirmation. Inpatients were subjects who received an ICD-9-CM diagnosis of acute pyelonephritis in the inpatient setting (i.e., at GH or an affiliate hospital) with or without confirmation by culture. Subjects who were initially seen as outpatients and were later hospitalized were considered to be inpatients. Date of diagnosis was designated as the date of the first recorded outpatient or inpatient ICD-9-CM code, and recurrent episodes were not included. Because we did not access patient charts, we did not further characterize patients as to risk factors for disease, such as pregnancy, diabetes, or urologic abnormalities.

**Culture, susceptibility, and treatment data.** Case patients were linked to automated data from affiliate hospitals were generally not available.

**Results.** We undertook 4 major analyses: trends in incidence, microbial etiology, antimicrobial resistance, and antimicrobial therapy. Denominator data for incidence rates used GH enrollment at the midpoint of each year. The $\chi^2$ test and $\chi^2$ test for trend were used to compare proportions, rates, and trends, with significance levels set at $P$ values of $\leq .01$. Statistical analyses were conducted using SAS software, version 9.1 (SAS), and Epi Info (Centers for Disease Control and Prevention).

**Results**

**Study population.** There were 4887 subjects with 10,330 ICD-9-CM diagnoses of acute pyelonephritis from January 1997 through December 2001. Of these, 2408 subjects (87% of whom were female) had culture-confirmed outpatient pyelonephritis and were included in these analyses (excluding 1651 outpatients without culture confirmation). A total of 828 subjects (79% of whom were female) had inpatient pyelonephritis; of these, 351 (40%) had culture confirmation.

**Trends in incidence.** Annual incidence rates of outpatient, inpatient, and total pyelonephritis from 1997 through 2001 are presented in figure 1. Over the 5-year period, rates of outpatient (12–13 cases per 10,000 population) and inpatient (3–4 cases per 10,000 population) pyelonephritis in the female population were several times higher than the respective rates in the male population (2–3 cases per 10,000 population and 1–2 cases per 10,000 population, respectively). Rates were relatively stable over time.

Among the female population, the incidence of outpatient pyelonephritis was elevated in girls aged 0–4 years but then decreased until a dramatic peak occurred in women aged 15–35 years (figure 2). Rates remained elevated but gradually decreased in older age groups until they again began to increase after 50 years of age. The highest incidence of inpatient pyelonephritis occurred in girls aged 0–4 years. Rates then decreased among individuals in early adolescence, followed by a small peak in women aged 15–35 years; rates gradually increased among patients aged >50 years, reaching a third peak at ~80
years of age. Outpatient rates were higher than inpatient rates among females of all age groups except young girls, most of whom were hospitalized. Among girls aged 0–4 years, 34% of outpatients and 57% of inpatients were aged <1 year.

Incidence rates of acute pyelonephritis were lower in the male population than in the female population for nearly every age group, although the difference in rates appeared to diminish at older ages. Males experienced a peak rate of outpatient pyelonephritis at 0–4 years of age, which was followed by a gradual increase in rates with older age, particularly after 35 years of age, that reached a separate, higher peak rate at 85 years of age. The highest rates of inpatient pyelonephritis also occurred in young boys and in the elderly population. After 0–4 years of age, rates were low until 50 years of age, after which they gradually increased. The incidence of inpatient pyelonephritis did not peak in the teenage years in boys as it did in girls. As observed in the female population, outpatient disease predominated in all age groups except for the youngest boys. Among boys aged 0–4 years, 80% of outpatients and 84% of inpatients were aged <1 year.

The ratio of outpatients to inpatients appeared to increase over time for girls aged 0–14 years (P = .05) and women aged 15–54 years (P = .17; figure 3). The ratio was highest for women aged 15–54 years (from 5:1 to 6:1). The ratio for boys aged 0–14 years ranged from 0.1 to 1.0, that for men aged 15–54 years ranged from 3 to 12, and that for men aged >=55 years ranged from 1 to 3 without a strong linear trend.

Acute pyelonephritis occurred most frequently during the months of July and August in the female population and during the months of August and September in the male population (figure 4). These month-to-month variations were statistically significant in adult women (P < .01, by χ² test).

**Trends in microbial etiology.** The distribution of causative uropathogens was similar for outpatients and inpatients (table 1). *E. coli* caused 81%–84% of pyelonephritis events among the female population. In the male population, a smaller percentage of pyelonephritis events (71%–74%) was associated with *E. coli* (P < .01, by χ² test for the difference between female and male patients), and uropathogens, such as *Klebsiella*, *Citrobacter*, and *Enterococcus* species, played a larger role. *S. saprophyticus* was isolated from a small percentage of female patients (2.8% of outpatients) and male patients (2.9% of inpatients and 0.9% of outpatients). There were no annual or monthly trends in the percentages of *E. coli*-associated pyelonephritis.

A lower percentage of pyelonephritis cases due to *E. coli* occurred in older patients, compared with younger age groups (table 2); this trend was statistically significant for female patients (P < .01). Other organisms were more frequently isolated
in persons ≥55 years of age, including Klebsiella and Enterococcus species, in particular. Among male patients, isolation of S. saprophyticus occurred predominantly among boys aged 0–14 years (6.8%). E. coli remained the predominant uropathogen in girls and boys aged <1 year.

**Trends in antimicrobial resistance.** Antimicrobial resistance data were available for pathogens isolated from 2137 (89%) of the outpatients and 303 (92%) of the inpatients with culture-confirmed cases. Uropathogen antimicrobial-resistance patterns were similar when stratified by treatment setting or by sex, and the data for all groups combined are shown in table 3. A trend of increasing resistance to cephalothin from 1997 through 2001 was noted (P<.01). The rate of fluoroquinolone resistance among E. coli strains was low, but it increased to 1.5% in 2001 (P = .03). Nonsignificant trends of decreasing rates of resistance among E. coli isolates were seen with gentamicin (P = .05) and nitrofurantoin (P = .02). Notably, the rate of E. coli with resistance to trimethoprim-sulfamethoxazole decreased significantly in 2001, from 23%–26% to 13% (P<.01). Yearly drug-resistance trends for E. coli and non–E. coli organisms combined also are presented in table 3. The rate of infection due to fluoroquinolone-resistant E. coli strains was lowest (0.0%) in girls and boys aged 0–14 years and highest (1.3%) in women and men aged ≥55 years (P = .01).

**Trends in antimicrobial therapy.** There were 2318 outpatients (96%) with prescription data available. Thirty-six percent of outpatients were prescribed multiple antibiotics. Seventy-three percent received oral antibiotics alone, 24% received oral and intravenous antibiotics, and 3% received intravenous antibiotics alone.

Several trends in antimicrobial use for outpatient treatment of acute pyelonephritis were noted (table 4). The frequency of fluoroquinolone use increased from 35% of outpatients in 1997 to 61% in 2001 (P<.01). There was a simultaneous decrease in the use of trimethoprim-sulfamethoxazole, from 53% of outpatients in 1997 to 32% in 2001 (P<.01). Third-generation cephalosporin use for the treatment of outpatient pyelonephritis nearly doubled over time, whereas the use of first-generation cephalosporins and nitrofurantoin decreased (P<.01).

Subjects aged 0–14 years with outpatient pyelonephritis were most frequently prescribed trimethoprim-sulfamethoxazole (rate of trimethoprim-sulfamethoxazole use, 61%). These subjects were rarely given fluoroquinolones. In contrast, fluoroquinolone use predominated for treatment of outpatient pyelonephritis among subjects aged 15–54 years (rate of fluoroquinolone use, 52%) and subjects ≥55 years of age (rate of fluoroquinolone use, 53%; P < .01, for trend with older age groups). The rate of trimethoprim-sulfamethoxazole use decreased with age.

**DISCUSSION**

To date, surprisingly few studies describe the epidemiology of acute pyelonephritis, which is a relatively common disease that causes substantial short-term morbidity and can lead to death or long-term complications. Still fewer studies are population based. Thus, our understanding of the societal impact of this disease is limited.

This study demonstrates that, over a recent 5-year interval in a large US population, cases of acute pyelonephritis were predominantly managed in the outpatient setting, particularly those cases occurring among young women. Earlier case series suggest that women with milder disease are largely treated as outpatients [16–19]. In a population-based study of acute pyelonephritis in South Korea, the incidence of disease among young adult women was 5 times greater among outpatients than among inpatients, which is similar to our results [14]. As in South Korea, elderly men and women at GH tended to receive outpatient treatment. Young children, however, were mostly hospitalized. The observed (nonsignificant) trend toward increasing outpatient treatment of girls likely reflects the
Table 1. Uropathogens isolated at time of acute pyelonephritis, 1997–2001.

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Percentage of isolates</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Female outpatients</td>
</tr>
<tr>
<td></td>
<td>(n = 2089)</td>
</tr>
<tr>
<td><em>Escherichia coli</em></td>
<td>81.6</td>
</tr>
<tr>
<td>Klebsiella species</td>
<td>2.6</td>
</tr>
<tr>
<td>Proteus species</td>
<td>1.2</td>
</tr>
<tr>
<td>Enterobacter species</td>
<td>1.3</td>
</tr>
<tr>
<td>Pseudomonas species</td>
<td>0.5</td>
</tr>
<tr>
<td>Citrobacter species</td>
<td>0.3</td>
</tr>
<tr>
<td>Enterococcus species</td>
<td>1.0</td>
</tr>
<tr>
<td>Staphylococcus saprophyticus</td>
<td>2.8</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>0.2</td>
</tr>
<tr>
<td>Other</td>
<td>8.5</td>
</tr>
</tbody>
</table>

* P < .01 for comparison between female and male patients (outpatients and inpatients combined), P = .27 for comparison between female outpatients and female inpatients, and P = .61 for comparison between male outpatients and male inpatients, by χ² test.

Table 2. Uropathogens isolated at time of acute pyelonephritis among both inpatients and outpatients, 1997–2001.

| Pathogen                  | Female patients        | Male patients       |
|---------------------------|------------------------|
|                           | 0–14 years (n = 301)   | 15–54 years (n = 1598) | ≥55 years (n = 452) | 0–14 years (n = 59) | 15–54 years (n = 139) | ≥55 years (n = 190) |
| *Escherichia coli*        | 88.0                   | 82.4               | 76.1              | 78.0              | 79.1               | 67.9               |
| Klebsiella species        | 1.7                    | 1.9               | 6.2               | 1.7               | 2.2               | 10.5               |
| Proteus species           | 1.0                    | 1.1               | 1.8               | 1.7               | 2.9               | 1.6                |
| Enterobacter species      | 0.7                    | 1.4               | 1.6               | 0.0               | 2.9               | 1.1                |
| Pseudomonas species       | 2.3                    | 0.3               | 0.4               | 0.0               | 2.2               | 2.1                |
| Citrobacter species       | 0.7                    | 0.2               | 0.4               | 1.7               | 2.2               | 2.6                |
| Enterococcus species      | 0.7                    | 0.6               | 2.6               | 1.7               | 2.2               | 6.8                |
| Staphylococcus saprophyticus| 0.3                   | 3.4               | 0.4               | 6.8               | 0.7               | 0.0                |
| Staphylococcus aureus     | 0.0                    | 0.3               | 0.2               | 3.4               | 0.7               | 0.0                |
| Other                     | 4.6                    | 8.4               | 10.3              | 5.0               | 4.9               | 7.4                |

* For female patients, P < .01, by χ² test for trend, for trend of decreasing percentage with older age group; for male patients, P = .04, by χ² test for trend, for trend of decreasing percentage with older age group.
women [13], E. coli was the leading cause of acute pyelonephritis. Of interest, the distribution of causative uropathogens did not appear to differ greatly between outpatients and inpatients and was similar to what was found in an earlier study of cystitis at GH [23]. It may be that host and other factors play a larger role in hospitalization and severity of disease [16, 18]. An unexpected finding was the frequency with which S. saprophyticus was isolated, particularly among boys. Although known to cause 15%–20% of cases of cystitis in young women [39], S. saprophyticus has been occasionally identified as a cause of acute pyelonephritis in women [13, 16]. This organism has not been described as a significant cause of UTI in men.

We noted concurrent trends of increasing fluoroquinolone resistance and decreasing trimethoprim-sulfamethoxazole resistance among E. coli strains over time and inverse trends in fluoroquinolone and trimethoprim-sulfamethoxazole use for outpatient treatment of acute pyelonephritis. Our data suggest that increasing fluoroquinolone use for treatment of UTI and other infections may be driving resistance. Our finding that fluoroquinolone resistance was greatest in the older age groups supports this hypothesis. Fluoroquinolone resistance was lowest among children, who are rarely treated with fluoroquinolones because of the known adverse effects. Increasing rates of fluoroquinolone resistance have been documented in the United States and Europe and have correlated with increased use [28, 30]. Although decreased use of trimethoprim-sulfamethoxazole for the treatment of cystitis has been documented elsewhere [28, 29], an accompanying decrease in trimethoprim-sulfamethoxazole resistance has not. In a previous study of cystitis at GH, trimethoprim-sulfamethoxazole resistance among E. coli isolates increased from 9% to 18% from 1992 to 1996 [23]. Of note, national guidelines for the treatment of UTI that were

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aminoglycoside</td>
<td>3.2</td>
<td>8.2</td>
<td>7.6</td>
<td>5.6</td>
<td>3.7</td>
</tr>
<tr>
<td>First-generation cephalosporin</td>
<td>12</td>
<td>12</td>
<td>5.7</td>
<td>6.9</td>
<td>4.8</td>
</tr>
<tr>
<td>Second-generation cephalosporin</td>
<td>0.0</td>
<td>0.4</td>
<td>0.4</td>
<td>1.0</td>
<td>0.4</td>
</tr>
<tr>
<td>Third-generation cephalosporin</td>
<td>12</td>
<td>23</td>
<td>26</td>
<td>25</td>
<td>23</td>
</tr>
<tr>
<td>Fluoroquinolone</td>
<td>36</td>
<td>33</td>
<td>52</td>
<td>58</td>
<td>61</td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>9.3</td>
<td>9.6</td>
<td>5.0</td>
<td>3.8</td>
<td>5.0</td>
</tr>
<tr>
<td>Penicillin derivative</td>
<td>7.9</td>
<td>8.8</td>
<td>10</td>
<td>7.5</td>
<td>5.4</td>
</tr>
<tr>
<td>TMP-SMX</td>
<td>53</td>
<td>52</td>
<td>41</td>
<td>35</td>
<td>32</td>
</tr>
</tbody>
</table>

NOTE. TMP-SMX, trimethoprim-sulfamethoxazole.

* Significance of linear trends from 1997 to 2001, determined by χ² test for trend.
published in 1999 advocate the use of alternatives to trimethoprim-sulfamethoxazole, including fluoroquinolones, in areas with elevated levels of trimethoprim-sulfamethoxazole resistance [15], and may have influenced subsequent treatment and drug-resistance patterns at GH. We did not find an increase in third generation cephalosporin resistance, despite an increase in the use of that class of antibiotic, and there was an increase in first-generation cephalosporin resistance, despite decreased use of first-generation cephalosporin.

This study has several strengths. GH provided a large well-defined population. We included outpatients and inpatients from both sexes and included subjects with a wide age range. Culture, antimicrobial-resistance, and antimicrobial-treatment data have not been included in other population-based studies of acute pyelonephritis.

Several limitations of our study should be mentioned. ICD-9-CM diagnoses are imprecise, in that it is difficult to distinguish codes associated with true disease from those that are not. We minimized this inaccuracy by restricting our analysis to first episodes and using culture-confirmation of outpatient cases. We may not have captured a small number of outpatient cases in which a subject was discharged from the emergency department of an affiliate hospital for which culture data were unavailable. Likewise, urine culture data were available for only 40% of inpatients (including those not hospitalized at GH affiliates), and misclassification of non–culture-confirmed inpatient cases was possible. Despite these limitations, a similar case definition was found to be 98% accurate in a previous study involving young adult women at GH [13]. Although our case definition has not been verified in other population age and sex subsets, we believe that the same methodological approach would be similarly accurate in these groups, as well. Finally, our treatment data were identified by their temporal relation to ICD-9-CM diagnoses and may reflect some antimicrobial resistance for unrelated conditions. For example, nitrofurantoin use, reported in 5%–10% of cases, may have been prescribed for episodes of cystitis that later progressed to pyelonephritis. Because treatment data for inpatients treated at affiliate hospitals were incomplete, we did not include an analysis of inpatient therapy.

Finally, our incidence rates were lower than those documented in other population-based studies [8, 9, 14], potentially because our more conservative case definition excluded recurrent disease and required culture-confirmation of outpatient cases. Previous study populations may also have differed from ours with respect to other risk factors for acute pyelonephritis. A detailed risk factor analysis, including a comparison of uncomplicated and complicated disease, was not possible using the databases available for this study.

In conclusion, in a comprehensive analysis of the epidemiology of acute pyelonephritis in a defined US population, we demonstrated that the great majority of cases are now managed in the outpatient setting, and we found significant changes in antimicrobial treatment and resistance patterns over time that mirror changes in the management of cystitis. To our knowledge, this is the first population-based study to describe, in detail, trends in the incidence, etiology, antimicrobial resistance, and antimicrobial therapy of acute pyelonephritis among outpatients in the United States. Further studies should address whether subsequent drug-resistance trends warrant changes in empirical recommendations for the treatment of this important infection.

Acknowledgments

We thank Jane Grafton, for her programming, and Onchee Yu, for her assistance with preparing the analysis files.

Financial support. National Institute of Diabetes and Digestive and Kidney Diseases (grants 5 P50 DK064540 and 5 P01 DK053369).

Potential conflicts of interest. All authors: no conflicts.

References


25. Talan DA, Stamm WE, Hooton TM. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA 2000; 283:1583–90.


